Selling to a third party a royalty on Zen3694 for upfront cash to support RVX BOM2 and its operations seems a long way off. 

I still say that a Zenith IPO ( with the help of Cencora) is the path of least resistance with many ZEN-3694 Clinical Trials ongoing in collaboration with various BP! And this provides its stakeholders liquidity as they see fit.

I note that Resverlogix is not being supported by Promororry Notes by insiders and their friends the same way as Zenith! The last bit of exempt distribution financing RVX amounted to $176K (CAN) in May 2023. According to its financials, RVX's cash position was $95K (US) on September 30, 2023. Management needs to advise its shareholders on how they intend to keep the company afloat other than the ad hoc approach of royalty from ZEN-3694.  

Koo (IMO)